Previous close | 9.61 |
Open | 9.57 |
Bid | 9.45 x 0 |
Ask | 9.90 x 0 |
Day's range | 9.57 - 9.68 |
52-week range | 7.20 - 10.33 |
Volume | |
Avg. volume | 96,487 |
Market cap | 2.024B |
Beta (5Y monthly) | 0.43 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.06 |
Earnings date | N/A |
Forward dividend & yield | 0.18 (1.94%) |
Ex-dividend date | 12 May 2023 |
1y target est | N/A |
Almirall, the Spanish pharmaceutical company, is on the brink of securing European Union (EU) approval for its IL-13 inhibitor lebrikizumab, marketed as Ebglyss, for atopic dermatitis treatment. The European Medicines Agency's (EMA) human medicines committee has recommended the drug's approval, setting up a challenge to the market-leading Dupixent, produced by Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN).
BARCELONA, Spain, September 15, 2023--Almirall S.A. (BME: ALM) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the marketing authorization of EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate-to-severe atopic dermatitis, who are candidates for systemic therapy.
BARCELONA, Spain, July 24, 2023--Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its H1 2023 financial results.